Study finds 1 in 12 patients labeled as having ‘benign’ results actually had high-risk prostate cancer

New research highlights the challenge of balancing the risks of overdiagnosing and underdiagnosing prostate cancer early enough to intervene and minimize risk of death. Recently, some experts have called for the lowest grade of prostate cancer—biopsy Gleason Grade Group (GGG) 1—to be reclassified as “benign.” But a new study led by a researcher from Mass General Brigham has found that many patients with a biopsy GGG1 may have a more aggressive cancer than their biopsy alone suggests.

​Medical Xpress – latest medical and health news stories

​Read More